Updated:
IRIDEX Corp
IRIDEX Corp, founded in 1989, develops proprietary MicroPulse laser systems for ophthalmology with an installed base in over 100 countries.
IRIDEX Corp
IRIDEX Corp was founded in 1989 and is headquartered in Mountain View, California. President and CEO David Bruce, a veteran of Boston Scientific and Stryker, joined the company in 2018 and accelerated a shift in focus toward the glaucoma market. Originally built around retinal photocoagulation, the firm's intellectual property now centers on its proprietary MicroPulse technology — a laser delivery mode designed to minimize thermal damage to surrounding tissue. The company operates two business segments: a core ophthalmology unit and a legacy aesthetic dermatology unit, though IRIDEX has publicly stated it aims to divest the aesthetic business to concentrate resources. Its ophthalmology portfolio includes the Cyclo G6 glaucoma laser system and the TX 33 and IQ 577 retinal lasers. MicroPulse Transscleral Laser Therapy (MP-TLT) has become a central product narrative, positioned as a repeatable, titratable alternative to traditional incisional glaucoma surgery. The installed base spans over 100 countries, supported by direct sales in the United States and distributor networks abroad, with key markets in Europe and Asia-Pacific. The firm maintains a team of roughly 100 employees and conducts manufacturing in its Mountain View facility. In August 2019, IRIDEX appointed Dr. Bruce as permanent CEO following his interim tenure, and the company has since released several next-generation MicroPulse probes aimed at expanding the technology's clinical utility. Clinical data published in 2020 from a multicenter study supported the use of MicroPulse in glaucoma management, reinforcing the company's regulatory and reimbursement narrative with Medicare and commercial payers. IRIDEX's structural differentiator is its dual-application proprietary laser technology and the annuity-like recurring revenue from single-use probe sales, which creates a consumables-driven model on top of its capital equipment installed base. The company's pivot to a pure-play ophthalmology strategy, if completed through the planned divestiture of its aesthetics segment, would make it a rare publicly traded company focused almost entirely on laser-based glaucoma therapies.
General information
Firm type
Other
Year founded
1989
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Mountain View
Corporate office
Mountain View, CA, United States
Principals
David Bruce
President & CEO
Sector focus
Frequently asked questions
What is IRIDEX's core technology?
IRIDEX owns patents on MicroPulse laser technology, a tissue-sparing delivery mode that uses repetitive, low-energy laser pulses to achieve a therapeutic effect without the thermal damage associated with traditional continuous-wave lasers. The technology is incorporated in its Cyclo G6 glaucoma system and retinal photocoagulation lasers.
How does IRIDEX make money?
The company generates revenue from the sale of capital equipment — laser consoles — and a recurring stream from disposable single-use probes and delivery devices required for each procedure. Its ophthalmology segment now drives the majority of revenue, following a strategic decision to divest its aesthetic dermatology unit.
Who runs the company?
Dr. David Bruce has served as President and CEO since August 2019, following an interim appointment in 2018. He previously held executive roles at Boston Scientific and Stryker, and brings medical device commercialization experience to IRIDEX's ophthalmology focus.
Where is IRIDEX's largest market?
The company sells directly in the United States and through distributor networks internationally, with a presence in more than 100 countries. Key international markets include Germany, Japan, China, and the broader European and Asia-Pacific regions, where its MicroPulse technology addresses a growing volume of glaucoma procedures.
What clinical evidence supports MicroPulse technology?
Peer-reviewed multicenter studies, including a landmark analysis published in 2020, have demonstrated that MicroPulse Transscleral Laser Therapy can achieve sustained intraocular pressure reduction with a favorable safety profile compared to continuous-wave cyclophotocoagulation. The company cites this data in its reimbursement and regulatory communications with FDA and CMS.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: